ESTRO 2022 - Abstract Book

S931

Abstract book

ESTRO 2022

1 Ramón y Cajal University Hospital, Radiation Oncology, Madrid, Spain; 2 Ramón y Cajal University Hospital , Physics, Madrid, Spain; 3 Ramón y Cajal University Hospital, Physics, Madrid, Spain Purpose or Objective The purpose of this study is to analyze the results of over 16 years of experience with postoperative radiochemotherapy based on weekly Cisplatin 40mg/m2 in patients diagnosed with locally advanced head and neck cancer. Materials and Methods Between March 2004 and April 2020, 133 consecutive patients diagnosed with resectable locally advanced head and neck cancer were treated in our department. All patients received adjuvant radiochemotherapy based on radiotherapy 66-70 Gy to areas with close surgical margin or extracapsular lymph node involvement and 50-54 Gy to the clinical target volume (CTV), concurrent with intravenous weekly cisplatin at 40mg/m2. Results The median age was 59 years (36-80), 106 patients were male (79.1%) and 27 were female (20.9%). The pathological stage were: 4 (3.0%) stage II, 13 (9.7%) stage III, 97 (72.9%) stage IVa and 19 (14.4%) stage IVb. Tumor sites: 46 (34.6%) larynx, 60 (45.1%) oral cavity, 20 (15.0%) oropharynx and 7 (5.3%) hypopharynx. 97 (72.9%) patients received at least 5 cycles of chemotherapy and 36 (27.1%) received less than 5 cycles of chemotherapy. 33 (24.8%) patients developed Grade III mucositis and 7 (5.3%) grade III neutropenia. After a median follow-up of 60 months (4-187), two and five-year overall survival (OS) were 76.9% and 59.5% respectively. Two and five-year cancer-specific survival were 82.6% and 70.3% respectively.

PATIENTS CHARACTERISTICS (N=133)

Gender Male Female

106 (79.1%)

27 (20.9%)

Age (years)

59 (36-80),

Patological Stage AJCC

II

4 (3.1%) 13 (9.7%) 97 (72.9%) 19 (14.3%%)

III

IVA IVB

Tumor sites Larynx Oral cavity Oropharynx Hypopharynx. Chemotherapy ≥ 5 cycles

46 (34.6%) 60 (44.9%) 20 (14.9%)

7 (5.6%)

97 (72.9%) 36 (27.1%)

<5 cycles

Grade III toxicity Mucositis

33 (24.8%)

Neutropenia

7 (5.26%)

Conclusion In our study, adjuvant radiochemotherapy based on intravenous weekly cisplatin at 40mg/m2 in patients with locally advanced head and neck cancer achieves a good toxicity profile and adequate compliance. Besides, cancer-specific survival and overall survival results were similar to those of cisplatin 100 mg/m2 every 3 weeks scheme published in the literature.

PO-1097 Helium-Neon laser to treat radiation induced oral mucositis in oral cancer- A comparative study

T. Nalawala 1 , S. Rath 1 , S. Kunikullaya 1 , K. Ratanchandani 1

1 The Gujarat Cancer and Research Institute, Radiation Oncology, Ahmedabad, India

Purpose or Objective